Mitsubishi Tanabe Pharma Corporation announced unaudited consolidated and non-consolidated earnings results for the year ended March 31, 2013. For the period, on consolidated basis, the company reported net income of ¥41,892 million or ¥74.67 per share, ordinary income of ¥69,392 million and operating income of ¥68,968 million on net sales of ¥419,179 million compared to net income of ¥39,014 million or ¥69.54 per share, ordinary income of ¥68,759 million and operating income of ¥69,043 million on net sales of ¥407,156 million for the same period a year ago. Return on equity was 5.7% compared to 5.5% at the same period a year ago. Net assets value per share was ¥1,333.22 compared to ¥1,275.85 for the same period a year ago. Net cash provided by operating activities were ¥60,589 million compared to ¥37,247 million for the same period a year ago. Income before income taxes and minority interests was ¥67,691 million compared to ¥63,788 million for the same period a year ago. Purchase of marketable securities was ¥64,250 million compared to ¥34,898 million for the same period a year ago. Purchase of property, plant and equipment was ¥8,681 million compared to ¥9,502 million for the same period a year ago. Purchase of intangible fixed assets was ¥2,142 million compared to ¥1,249 million for the same period a year ago. Purchase of investment in securities was ¥6,830 million compared to ¥1,407 million for the same period a year ago. For the period, on non-consolidated basis, the company reported net income of ¥54,602 million or ¥97.33 per share, ordinary income of ¥76,205 million and operating income of ¥72,937 million on net sales of ¥396,542 million compared to net income of ¥44,368 million or ¥79.08 per share, ordinary income of ¥69,611 million and operating income of ¥67,217 million on net sales of ¥389,151 million for the same period a year ago. Net assets value per share was ¥1,097.67 compared to ¥1,025.45 for the same period a year ago. The company also provided interim and full year earnings guidance for the fiscal 2013 ended on March 31, 2014. For the interim period, the company expected net income of ¥19,000 million or ¥33.87 per share, ordinary income of ¥31,000 million and operating income of ¥30,000 million on net sales of ¥200,000 million. For the full year, the company expected net income of ¥44,000 million or ¥78.43 per share, ordinary income of ¥71,500 million and operating income of ¥70,000 million on net sales of ¥417,000 million.

Mitsubishi Tanabe Pharma Corporation, 2013 Earnings Call, May 09, 2013

Mitsubishi Tanabe Pharma Corporation announced that they will report fiscal year 2013 results on May 08, 2013